NEOADJUVANT COMBINATION THERAPY OF DOCETAXEL AND COMPLETE ANDROGEN DEPRIVATION FOR LOCALIZED HIGH RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY

被引：0
|
作者：
Thalgott, M. K. [1 ]
Treiber, U. [1 ]
Maurer, T. [1 ]
Heck, M. [1 ]
Eiber, M. [2 ,3 ]
Reimer, B. [1 ]
Herkommer, K. [1 ]
Paul, R.
Retz, M. [1 ]
Gschwend, J. E. [1 ]
Kuebler, H. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D-8000 Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiol, D-8000 Munich, Germany
[3] Urol Ctr Furstenfeldbruck Germering, Dept Urol, Munich, Germany
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(10)60675-6
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：226 / 226
页数：1
相关论文
共 50 条
  • [21] Phase II trial of weekly docetaxel and complete androgen blockade prior to radical prostatectomy in high-risk localized prostate cancer patients
    Font, Albert
    Mellado, Begona
    Aparicio, Luis A.
    Gallardo, Enrique
    Mel, Ramon
    Alcaraz, Antonio
    Areal, Juan
    Gomez Veiga, Francisco J.
    Hannaoui, Nahim
    Gascon, Pere
    ANNALS OF ONCOLOGY, 2006, 17 : 146 - 146
  • [22] Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
    Beltran, Himisha
    Wyatt, Alexander W.
    Chedgy, Edmund C.
    Donoghue, Adam
    Annala, Matti
    Warner, Evan W.
    Beja, Kevin
    Sigouros, Michael
    Mo, Fan
    Fazli, Ladan
    Collins, Colin C.
    Eastham, James
    Morris, Michael
    Taplin, Mary-Ellen
    Sboner, Andrea
    Halabi, Susan
    Gleave, Martin E.
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6802 - 6811
  • [23] Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer - Discussion
    Daniell, HW
    Meyer, F
    UROLOGY, 2001, 58 (2A) : 77 - 77
  • [24] Combination of radiotherapy and androgen deprivation therapy for localized prostate cancer
    Hennequin, C.
    Fumagalli, I.
    Martin, V.
    Quero, L.
    CANCER RADIOTHERAPIE, 2017, 21 (6-7): : 462 - 468
  • [25] Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase II study
    Cookson, MS
    Sogani, PC
    Russo, P
    Sheinfeld, J
    Herr, H
    Dalbagni, G
    Reuter, VE
    Begg, CB
    Fair, WR
    BRITISH JOURNAL OF UROLOGY, 1997, 79 (03): : 432 - 438
  • [26] Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer
    Perera, Marlon
    Beech, Benjamin B.
    Escano, Manuel De Jesus
    Gmelich, Caroline
    Yip, Wesley
    Boorjian, Stephen A.
    Eastham, James A.
    FRONTIERS IN UROLOGY, 2022, 2
  • [27] The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer
    Ebara, Shin
    Manabe, Daisuke
    Kobayashi, Yasuyuki
    Tanimoto, Ryuta
    Saika, Takashi
    Nasu, Yasutomo
    Saito, Shirou
    Satoh, Takefumi
    Miki, Kenta
    Hashine, Katsuyoshi
    Kumon, Hiromi
    ACTA MEDICA OKAYAMA, 2007, 61 (06) : 335 - 340
  • [28] Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
    Wei, Yongbao
    Zhang, Ruochen
    Zhong, Dewen
    Chen, Zhensheng
    Chen, Gen
    Yang, Minggen
    Lin, Le
    Li, Tao
    Ye, Liefu
    Chen, Lili
    Zhu, Qingguo
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [29] Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer
    Hammerer, P.
    Manka, L.
    UROLOGE, 2019, 58 (10): : 1185 - 1197
  • [30] Initial therapy with radical prostatectomy for high risk localized prostate cancer
    Montie, James E.
    JOURNAL OF UROLOGY, 2006, 176 (06): : S27 - S29
12345